Key facts
- Notable investors include CICC Capital, Yixing Jieyi Private Equity Fund Management, Guangzhou Financial Holdings, Kangtai Health, Sunshine Ronghui Capital Investment Management.
- Status: Privately Held (backing).
- ·The complete investor list — 5 names
- ·Watchlist + deal alerts for tricision
- ·The full record, as it builds
Funding rounds
No funding rounds for tricision are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About tricision
Developer of research and product and production technology platform designed for messenger ribonucleic acid (mRNA) nucleic acid drugs. The company's technologies provide solutions for the prevention and treatment of cancer, infectious diseases, autoimmune diseases, genetic diseases, and more, enabling researchers and medical professionals to protect human health and life.
- Sector
- Healthcare
- HQ
- Beijing, China
- Founded
- 2015
- Employees
- 100
- Website
- tricisionbio.com/
- Ownership
- Privately Held (backing)
tricision doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in tricision shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on tricision in its N-PORT filings yet. We sweep new filings monthly.